▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Halozyme Therapeutics (NASDAQ: HALO)

$74.94

(2.2%)

$1.60

Price as of October 1, 2025, 4:00 p.m. ET

Halozyme Therapeutics Return vs. S&P

	1 Year	5 Year	5 Year Annualized	Since IPO
HALO	+32.31%	+190.35%	+23.76%	+1,667%
S&P	+17.56%	+100.43%	+14.92%	+499%

Halozyme Therapeutics Company Info

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

News & Analysis

The Fool has written over 100 articles on Halozyme Therapeutics.

Featured Article

Top Biotech ETFs to Buy Now

Here are the five best biotech ETFs to invest in right now.

Keith Speights | Oct 1, 2025

Featured Article

Halozyme (HALO) Q2 EPS Jumps 69%

Motley Fool Markets Team | Aug 5, 2025

How to Invest in iShares Russell 2000 ETF

Robin Hartill | Jun 6, 2025

Would Halozyme Make a Good Warren Buffett Stock?

Alex Carchidi | Apr 4, 2021

In some ways, this healthcare stock is outside his wheelhouse. But there could be attractions.

Are Biotech Stocks a Good Hedge Against Higher Inflation?

Alex Carchidi | Mar 27, 2021

It's worth putting a few of your eggs into this basket if you're worried about a big increase in prices.

Why Halozyme Therapeutics Is Trading 14% Higher Today

Eric Volkman | Feb 24, 2021

Investors liked what they saw in the company's fourth-quarter earnings release.

Can Halozyme Therapeutics Continue Its Momentum in 2020?

Amar Khatri | Mar 2, 2020

The biopharma's strategic moves in 2019 may set the company up for long term growth.

3 Cancer Treatment Stocks to Buy in March

Brian Feroldi, Chuck Saletta, and Todd Campbell | Mar 23, 2019

Find out why these oncology-focused companies stand out as great opportunities right now.

Valuation

Earnings Transcripts

Halozyme Therapeutics, inc (HALO) Q3 2021 Earnings Call Transcript

HALO earnings call for the period ending September 30, 2021.

Motley Fool Transcribers | Nov 3, 2021

Halozyme Therapeutics, inc (HALO) Q2 2021 Earnings Call Transcript

HALO earnings call for the period ending June 30, 2021.

Motley Fool Transcribers | Aug 9, 2021

Halozyme Therapeutics Inc (HALO) Q1 2021 Earnings Call Transcript

HALO earnings call for the period ending March 31, 2021.

Motley Fool Transcribers | May 10, 2021

Halozyme Therapeutics Inc (HALO) Q4 2020 Earnings Call Transcript

HALO earnings call for the period ending December 31, 2020.

Motley Fool Transcribers | Feb 23, 2021

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services